Cover Image
Market Research Report

Global Conjunctivitis Therapeutics Market 2019-2023

Published by TechNavio (Infiniti Research Ltd.) Product code 785671
Published Content info 115 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Conjunctivitis Therapeutics Market 2019-2023
Published: February 4, 2019 Content info: 115 Pages
Description

About this market

Conjunctivitis is inflammation in the inside of the eyelids and the covering of the white of the eye, which causes the conjunctival blood vessels to dilate. While allergic conjunctivitis is known to be prevalent among people with allergies, infectious conjunctivitis is known to spread at a very fast rate. The ease of availability of antibiotic eye drops and ointments for the treatment of bacterial conjunctivitis and antibiotics for viral conjunctivitis is leading to an increase in the use of these therapeutics. The use of therapeutics is primarily to avoid the progression of the disease into severe indications, which could increase the economic burden of patients. Hence, the infectious nature of the disease is expected to increase the adoption rate of therapeutics, thus resulting in the growth of the market during the forecast period. Technavio's analysts have predicted that the conjunctivitis therapeutics market will register a CAGR of over 8% by 2023.

Market Overview

Growing allergy cases

Allergic conjunctivitis is caused by various types of allergies such as hay fever and asthma. Being allergic to substances such as dust mites and mold can also increase the risk of infection. Globally. the prevalence of various types of allergies has been growing at a significant rate. The increasing prevalence of allergies such as dust mite allergy and pollen allergy increase the risk of allergic conjunctivitis.

Patent cliff

One of the major challenges faced by the global conjunctivitis therapeutics market is the patent expiration of various drugs in the market. Patent expiration leads to the increasing launch of generic drugs, thereby leading to value erosion of the global market. The patent expiry of blockbuster drugs also impacts the sales of the vendors significantly, making it difficult for vendors to compete in the market. Thus, the patent expiry of blockbuster drugs and the subsequent entry of generics restrict market growth.

For the detailed list of factors that will drive and challenge the growth of the conjunctivitis therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be concentrated and with the presence of very few vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Table of Contents
Product Code: IRTNTR30814

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1. Preface
  • 2.2. Preface
  • 2.3. Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Allergic conjunctivitis - Market size and forecast 2018-2023
  • Bacterial conjunctivitis - Market size and forecast 2018-2023
  • Viral conjunctivitis - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Akorn, Incorporated
  • ALLERGAN
  • Bausch Health
  • Novartis AG
  • Santen Pharmaceutical Co., Ltd.

PART 13: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Type - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Allergic conjunctivitis - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Allergic conjunctivitis - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Bacterial conjunctivitis - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Bacterial conjunctivitis - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Viral conjunctivitis - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 25: Viral conjunctivitis - Year-over-year growth 2019-2023 (%)
  • Exhibit 26: Market opportunity by type
  • Exhibit 27: Customer landscape
  • Exhibit 28: Market share by geography 2018-2023 (%)
  • Exhibit 29: Geographic comparison
  • Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 31: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 37: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Key leading countries
  • Exhibit 39: Market opportunity
  • Exhibit 40: Decision framework
  • Exhibit 41: Impact of drivers and challenges
  • Exhibit 42: Vendor landscape
  • Exhibit 43: Landscape disruption
  • Exhibit 44: Vendors covered
  • Exhibit 45: Vendor classification
  • Exhibit 46: Market positioning of vendors
  • Exhibit 47: Akorn, Incorporated - Vendor overview
  • Exhibit 48: Akorn, Incorporated - Business segments
  • Exhibit 49: Akorn, Incorporated - Organizational developments
  • Exhibit 50: Akorn, Incorporated - Segment focus
  • Exhibit 51: Akorn, Incorporated - Key offerings
  • Exhibit 52: Akorn, Incorporated - Key customers
  • Exhibit 53: ALLERGAN - Vendor overview
  • Exhibit 54: ALLERGAN - Product segments
  • Exhibit 55: ALLERGAN - Organizational developments
  • Exhibit 56: ALLERGAN - Geographic focus
  • Exhibit 57: ALLERGAN - Segment focus
  • Exhibit 58: ALLERGAN - Key offerings
  • Exhibit 59: ALLERGAN - Key customers
  • Exhibit 60: Bausch Health - Vendor overview
  • Exhibit 61: Bausch Health - Business segments
  • Exhibit 62: Bausch Health - Organizational developments
  • Exhibit 63: Bausch Health - Geographic focus
  • Exhibit 64: Bausch Health - Segment focus
  • Exhibit 65: Bausch Health - Key offerings
  • Exhibit 66: Bausch Health - Key customers
  • Exhibit 67: Novartis AG - Vendor overview
  • Exhibit 68: Novartis AG - Business segments
  • Exhibit 69: Novartis AG - Organizational developments
  • Exhibit 70: Novartis AG - Geographic focus
  • Exhibit 71: Novartis AG - Segment focus
  • Exhibit 72: Novartis AG - Key offerings
  • Exhibit 73: Novartis AG - Key customers
  • Exhibit 74: Santen Pharmaceutical Co., Ltd. - Vendor overview
  • Exhibit 75: Santen Pharmaceutical Co., Ltd. - Business segments
  • Exhibit 76: Santen Pharmaceutical Co., Ltd. - Organizational developments
  • Exhibit 77: Santen Pharmaceutical Co., Ltd. - Geographic focus
  • Exhibit 78: Santen Pharmaceutical Co., Ltd. - Segment focus
  • Exhibit 79: Santen Pharmaceutical Co., Ltd. - Key offerings
  • Exhibit 80: Santen Pharmaceutical Co., Ltd. - Key customers
  • Exhibit 81: Validation techniques employed for market sizing
  • Exhibit 82: List of abbreviations
Back to Top